The CATT Research Group April 2011 In 2005, clinical trials established the efficacy of ranibizumab (Lucentis, Genentech) for the treatment of neovascular age-related macular degeneration (AMD), the leading cause of legal blindness in the United States. While awaiting approval for ranibizumab from the Food and Drug Administration, ophthalmologists began treating neovascular AMD with off-label use [Read More]
